DJIA 18,037.97 -42.17 -0.23%
NASDAQ 5,060.25 -31.84 -0.63%
S&P 500 2,108.92 -8.77 -0.41%
market minute promo

9.41 -0.65 (-6.46%)

REAL-TIME: Last trade at

Extended Hours: $9.39 -$0.02 (-0.21%)
Quote as of (NASDAQ)



company name or ticker

Recent Quotes

ACHN $9.41 -6.46%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $10.21
Previous Close $10.06
Daily Range $9.39 - $10.36
52-Week Range $2.45 - $16.87
Market Cap $1.1B
P/E Ratio -14.37
Dividend (Yield) $0.00 (0.0%)
Volume 4,584,744
Average Daily Volume 2,523,522
Current FY EPS -$0.96

Sector

Healthcare

Industry

Drug Makers

ACHILLION PHARMACEUTICALS, INC. (ACHN) Description

A biopharmaceutical company focuses on the discovery, development and commercialization of innovative treatments for infectious diseases Website: http://www.achillion.com/

News & Commentary Rss Feed

3 Biotech Stocks That Could Be Developing Billion Dollar Drugs

These three clinical stage biotech companies are working on therapies addressing billion dollar indications.

Positioning For A Catalyst-Heavy 2015 In Achillion Pharmaceuticals

The Best Stock to Invest in Hep C

In the multibillion-dollar market for hepatitis C, this company stands above the crowd.

The Biotech Stocks JMP Is Watching

Gilead Experiencing Bumpy Ride Despite Strong Fundamentals

Should Gilead Sciences, Inc. Be Worried By Achillion Pharmaceuticals?

Achillion Pharmaceuticals' ACH-3102 and ACH-3422 could eventually offer up an alternative to Gilead Sciences' HCV medicines.

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals

The Zacks Analyst Blog Highlights: Gilead Sciences, Bristol-Myers Squibb, Achillion Pharmaceuticals and Cambrex - Press Releases

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the

Falling Earnings Estimates Signal Weakness Ahead for Achillion Pharmaceuticals (ACHN) - Tale of the Tape

Is Gilead Sciences Inc. About to Crater Before Our Very Eyes?

Gilead Sciences has become a battleground stock due to the uncertainty surrounding the future of the hep C market. Here is a look at why the bears might be right in their assessment of this top biotech stock.

Gilead's Hepatitis C Drug Sovaldi Gets Approval in Japan - Analyst Blog

See More ACHN News...

ACHN's Top Competitors

ACHN $9.41 (-6.46%)
Current stock: ACHN
AMGN $162.38 (-3.29%)
Current stock: AMGN
GILD $102.94 (-0.73%)
Current stock: GILD
BIIB $389.27 (-3.10%)
Current stock: BIIB